Tibolone vaginal versus per os administration in the management of post-menopausal symptoms

dc.contributor.author	Ζερβούδης, Στέφανος	el
dc.contributor.author	Ιατράκης, Γεώργιος Μ.	el
dc.contributor.author	Πεϊτσίδης, Παναγιώτης	el
dc.contributor.author	Τσίκουρας, Παναγιώτης	el
dc.contributor.author	Γαλάζιος, Γεώργιος	el
dc.date.accessioned	2015-05-12T16:48:37Z
dc.date.issued	2015-05-12
dc.identifier.uri	http://hdl.handle.net/11400/10225
dc.rights	Αναφορά Δημιουργού-Μη Εμπορική Χρήση-Όχι Παράγωγα Έργα 3.0 Ηνωμένες Πολιτείες	*
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/3.0/us/	*
dc.source	http://www.ncbi.nlm.nih.gov/pubmed/21491823	en
dc.subject	Steroid hormones--Therapeutic use
dc.subject	Nutrition
dc.subject	Psychological support
dc.subject	Στεροειδής ορμόνες, Θεραπευτικές ιδιότητες
dc.subject	Διατροφή
dc.subject	Ψυχολογική υποστήριξη
dc.title	Tibolone vaginal versus per os administration in the management of post-menopausal symptoms	en
heal.type	journalArticle
heal.classification	Medicine
heal.classification	Gynecology
heal.classification	Ιατρική
heal.classification	Γυναικολογία
heal.classificationURI	http://id.loc.gov/authorities/subjects/sh00006614
heal.classificationURI	http://id.loc.gov/authorities/subjects/sh85058092
heal.classificationURI	N/A-Ιατρική
heal.classificationURI	N/A-Γυναικολογία
heal.keywordURI	http://id.loc.gov/authorities/subjects/sh85128056
heal.keywordURI	http://skos.um.es/unescothes/C02780
heal.contributorName	Λυμπέρης, Βασίλειος	el
heal.contributorName	Ναυρόζογλου, Ιορδάνης	el
heal.contributorName	Ceauşu, I.	fr
heal.contributorName	Badiu, C.	en
heal.dateAvailable	10000-01-01
heal.language	en
heal.access	forever
heal.recordProvider	Σχολή Επαγγελμάτων Υγείας και Πρόνοιας. Τμήμα Μαιευτικής	el
heal.publicationDate	2009
heal.bibliographicCitation	Zervoudis, S., Iatrakis, G., Peitsidis, P., Tsikouras, P., Galazios, G., et al. (2009) Tibolone vaginal versus per os administration in the management of post-menopausal symptoms. In "Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi", 113 (2), p. 471-477. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21491823 [Accessed: 12/05/2015].	en
heal.abstract	Tibolone is a selective tissue estrogenic activity regulator effective in the management of climacteric symptoms, without stimulating endometrial and breast tissue proliferation. It is a well-tolerated treatment regimen with minor adverse effects. The purpose of the current trial was to investigate the efficacy of tibolone administration per os versus per vaginal, concerning the treatment of climacteric symptoms. MATERIAL AND METHOD: A total of 64 post-menopausal healthy women aged 44-55 years (mean 52,5) were enrolled in the study. The patients were divided into three groups: Group A with 24 patients receiving per os Tibolone 2.5 mg x 1 daily for 6 months, Group B with 21 patients receiving vaginally Tibolone 2.5 mg x 1 for 6 months and Group C--with 19 patients receiving only hygienodietetics advices and psychological support for 6 months. All subjects underwent a physical examination, including a transvaginal ultrasonography for the measurement of endometrial thickness and a mammography for the assessment of breast density. RESULTS: In Group A and B, climacteric symptoms were similarly reduced with non significant differences between groups: 79% (19 patients) vs 76% (16 patients) reduction for hot flushes and 83% (20 patients) vs 76% (16 patients) for sweating episodes respectively (p > 0.05). Reduction of hot flushes and sweating episodes was observed in only 2 of 19 patients (10.5%) in group C (p < 0.01). Vaginal route had better results on vaginal dryness-dyspareunia in group B (in 14 patients taken tibolone orally-58% vs 16 patients taken tibolone vaginally-76%). No statistically significant difference was found related to urine symptoms between A and B groups. Tibolone by vaginal route did not cause any severe side effects (apart of a slight discharge) and it was equally (or better) tolerated than oral route. No significant alterations in breast density and BIRADS and no increase in endometrial thickness were observed in all study groups. CONCLUSION: Tibolone is effective in relieving climacteric symptoms indifferent from applications-modus: orally or vaginally. However, further and larger studies are required to confirm results.	en
heal.publisher	US National Library of Medicine	en
heal.journalName	Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi	en
heal.journalType	peer-reviewed
heal.fullTextAvailability	false